fMRI connectivity as a biomarker of antipsychotic treatment response: A systematic review
- PMID: 37797435
- PMCID: PMC10568423
- DOI: 10.1016/j.nicl.2023.103515
fMRI connectivity as a biomarker of antipsychotic treatment response: A systematic review
Abstract
Background: Antipsychotic drugs are the first-choice therapy for psychotic episodes, but antipsychotic treatment response (AP-R) is unpredictable and only becomes clear after weeks of therapy. A biomarker for AP-R is currently unavailable. We reviewed the evidence for the hypothesis that functional magnetic resonance imaging functional connectivity (fMRI-FC) is a predictor of AP-R or could serve as a biomarker for AP-R in psychosis.
Method: A systematic review of longitudinal fMRI studies examining the predictive performance and relationship between FC and AP-R was performed following PRISMA guidelines. Technical and clinical aspects were critically assessed for the retrieved studies. We addressed three questions: Q1) is baseline fMRI-FC related to subsequent AP-R; Q2) is AP-R related to a change in fMRI-FC; and Q3) can baseline fMRI-FC predict subsequent AP-R?
Results: In total, 28 articles were included. Most studies were of good quality. fMRI-FC analysis pipelines included seed-based-, independent component- / canonical correlation analysis, network-based statistics, and graph-theoretical approaches. We found high heterogeneity in methodological approaches and results. For Q1 (N = 17) and Q2 (N = 18), the most consistent evidence was found for FC between the striatum and ventral attention network as a potential biomarker of AP-R. For Q3 (N = 9) accuracy's varied form 50 till 93%, and prediction models were based on FC between various brain regions.
Conclusion: The current fMRI-FC literature on AP-R is hampered by heterogeneity of methodological approaches. Methodological uniformity and further improvement of the reliability and validity of fMRI connectivity analysis is needed before fMRI-FC analysis can have a place in clinical applications of antipsychotic treatment.
Keywords: Antipsychotic response; Functional connectivity; Prediction; Psychosis; fMRI.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures






Similar articles
-
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.Cochrane Database Syst Rev. 2015 Jan 16;1(1):CD009831. doi: 10.1002/14651858.CD009831.pub2. Cochrane Database Syst Rev. 2015. PMID: 25592299 Free PMC article.
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Pharmacological interventions for those who have sexually offended or are at risk of offending.Cochrane Database Syst Rev. 2015 Feb 18;2015(2):CD007989. doi: 10.1002/14651858.CD007989.pub2. Cochrane Database Syst Rev. 2015. PMID: 25692326 Free PMC article.
-
Pharmacological treatment of children with gastro-oesophageal reflux.Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD008550. doi: 10.1002/14651858.CD008550.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2023 Aug 22;8:CD008550. doi: 10.1002/14651858.CD008550.pub3. PMID: 25419906 Free PMC article. Updated.
-
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2. Cochrane Database Syst Rev. 2021. PMID: 34697802 Free PMC article.
Cited by
-
The Role of Temperament Traits in Bipolar Disorder: Neuroimaging Study.Depress Anxiety. 2025 May 10;2025:5974860. doi: 10.1155/da/5974860. eCollection 2025. Depress Anxiety. 2025. PMID: 40384807 Free PMC article.
-
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelb). 2025 Apr 2;11(1):52. doi: 10.1038/s41537-025-00581-6. Schizophrenia (Heidelb). 2025. PMID: 40175382 Free PMC article.
-
The functional near infrared spectroscopy applications in children with developmental diseases: a review.Front Neurol. 2025 Jun 17;16:1495138. doi: 10.3389/fneur.2025.1495138. eCollection 2025. Front Neurol. 2025. PMID: 40599736 Free PMC article. Review.
References
-
- American Psychiatric Association, editor. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013.
-
- Anon. WHO ATC/DDD Index 2020. WHO Collaborating Centre for Drugs Statistics Methodology.
-
- Anticevic A., Hu X., Xiao Y., Hu J., Li F., Bi F., Cole M.W., Savic A., Yang G.J., Repovs G., Murray J.D., Wang X.-J., Huang X., Lui S.u., Krystal J.H., Gong Q. Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change. J. Neurosci. 2015;35(1):267–286. - PMC - PubMed
-
- Birn R.M., Diamond J.B., Smith M.A., Bandettini P.A. Separating respiratory-variation-related fluctuations from neuronal-activity-related fluctuations in fMRI. Neuroimage. 2006;31(4):1536–1548. - PubMed
Further reading
-
- Olanzapine 2.5 mg tablets - Summary of Product Characteristics (SmPC) - (emc). Accessed September 8, 2021. https://www.medicines.org.uk/emc/product/3097/smpc#gref.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous